RISE Challenge Award Ceremony

RISE Challenge Award Ceremony

Teva Pharmaceuticals’ Venture Arm, RISE, and Nefesh B’Nefesh recently recognized Keheala with two innovation awards.

The RISE Challenge, a global “innovation competition aiming to find novel solutions to real patient needs worldwide” was launched in 2016 to identify the most innovative solutions in several categories of care (Diagnostics, Inhaler Design, etc.). Keheala was selected as the winner of the Digital Health category. This award recognizes Keheala’s “potential for significant impact on the health and wellness of millions of people throughout the world in terms of effectiveness and reach.” The award was announced at a December ceremony with RISE executives in attendance. As a part of the award, Keheala has received a cash prize. This is the first award Keheala has received from a major pharmaceutical company.

Nefesh B’Nefesh awarded Keheala the Initiative for Zionist Innovation (IZI) award, which seeks “the next generation of leaders and innovators.” A cash prize was received by Keheala as part of this recognition.

Keheala delivers behavioral interventions across mobile phones to improve healthcare access and treatment outcomes for infectious and chronic disease patients across the developing world. In a 1200 patient randomized controlled trial, tuberculosis patients using Keheala's intervention demonstrated a two-thirds reduction in the unsuccessful treatment outcomes of death, failed treatment and loss to follow up.

RISE is a venture arm of Teva Pharmaceuticals aiming to transform healthcare in growth markets, bringing hope and healthcare access to billions of people around the world. Addressing local needs and challenges, RISE strives to design and deploy integrated healthcare solutions, with partners, based on technology and business model innovation.

Nefesh B’Nefesh is an organization dedicated to helping individuals ‘from North America and the UK by removing or minimizing the financial, professional, logistical and social obstacles of Aliyah.”

For inquiries, please e-mail